11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose studyJuha O. Rinne, Michael Grundman, Martin N. Rossor et al.|The Lancet Neurology|2010Cited by 696